Keywords: GlaxoSithKline, Theravance, Human Genome Sciences, FF/VI, Relovair, Relvar, Breo, Regulatory filings, Europe, USA, M&A

GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with Human Genome?

Article | 16 July 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced on Friday that they had submitted regulatory ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in